SDZ 64-412: structure given in first source; PAF antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 159547 |
| CHEMBL ID | 449395 |
| SCHEMBL ID | 9118339 |
| MeSH ID | M0161381 |
| Synonym |
|---|
| bdbm50041921 |
| 5-{4-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-phenyl}-2,3-dihydro-imidazo[2,1-a]isoquinoline |
| gtpl1855 |
| sdz 64-412 |
| L024111 |
| CHEMBL449395 , |
| sdz-64-412 |
| SCHEMBL9118339 |
| 5-[4-[2-(3,4,5-trimethoxyphenyl)ethyl]phenyl]-2,3-dihydroimidazo[2,1-a]isoquinoline |
| HY-U00040 |
| paf-an-1 |
| CS-7323 |
| 115621-84-6 |
| Q27088770 |
| AKOS040740987 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The bioavailability of the parent drug, calculated by dose-normalized AUC and deconvolution methods, was only 10-15% from the low dose, but increased to approximately 40% following the high dose." | ( Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat. Athill, LV; Charnick, SB; Karara, AH; Lau, DT; Tse, FL; Yu, Z, 1994) | 0.29 |
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pharmacokinetics of SDZ 64-412, an antiasthmatic agent, were investigated following intravenous, oral, and inhalation dosing in rats." | ( Pharmacokinetics of SDZ 64-412, a novel antiasthmatic agent, following intravenous, oral, and inhalation dosing in the rat. Athill, LV; Charnick, SB; Karara, AH; Lau, DT; Tse, FL; Yu, Z, 1994) | 0.29 |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Platelet-activating factor receptor | Homo sapiens (human) | IC50 (µMol) | 0.0600 | 0.0003 | 0.6318 | 3.7000 | AID154467 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| lipopolysaccharide binding | Platelet-activating factor receptor | Homo sapiens (human) |
| lipopolysaccharide immune receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| G protein-coupled receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| platelet activating factor receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| protein binding | Platelet-activating factor receptor | Homo sapiens (human) |
| phospholipid binding | Platelet-activating factor receptor | Homo sapiens (human) |
| mitogen-activated protein kinase binding | Platelet-activating factor receptor | Homo sapiens (human) |
| G protein-coupled purinergic nucleotide receptor activity | Platelet-activating factor receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| secretory granule membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| tertiary granule membrane | Platelet-activating factor receptor | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID77109 | In vivo PAF induced hemoconcentration tested in guinea pig | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists. |
| AID77108 | In vivo PAF induced bronchoconstriction tested in guinea pig | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists. |
| AID154467 | In vitro PAF antagonistic activity by determining [3H]PAF binding to the PAF-receptor of human platelets | 1993 | Journal of medicinal chemistry, Oct-15, Volume: 36, Issue:21 | Structural modification of 5-aryl-2,3-dihydroimidazo[2,1-a]isoquinoline platelet activating factor receptor antagonists. |
| AID1346403 | Human PAF receptor (Platelet-activating factor receptor) | 1988 | The Journal of pharmacology and experimental therapeutics, Nov, Volume: 247, Issue:2 | Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 5 (83.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||